A Phase 1, Non-randomized, Open-label, Single-dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of Pf-04965842 In Subjects With Renal Impairment And In Healthy Subjects With Normal Renal Function
Phase of Trial: Phase I
Latest Information Update: 21 Nov 2018
At a glance
- Drugs Abrocitinib (Primary)
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 07 Nov 2018 Planned End Date changed from 1 Dec 2019 to 6 Dec 2019.
- 07 Nov 2018 Planned primary completion date changed from 1 Nov 2019 to 4 Nov 2019.
- 11 Oct 2018 Status changed from not yet recruiting to recruiting.